Video
Increased financial coverage for Rezum therapy reaps benefits for patients with BPH
Author(s):
“I think now the government has realized…the work that’s involved in this procedure…[and] we’re now being reimbursed at an appropriate level,” says David M. Albala, MD.
Video Player is loading.
In this video, David M. Albala, MD, discusses how the recent change made by the Centers for Medicare & Medicaid Services regarding Rezum water vapor therapy will open the doors for more patients to receive this minimally invasive treatment. Albala is a urologist at Associate Medical Professionals and chief of urology at Crouse Hospital in Syracuse, New York.
Related Videos
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Clinical Benefits of BPH Treatments
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Jason Hafron, MD, outlines AUA 2025 session on clinical trial recruitment
Related Content
